Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Share suspension lifted, following the publication of its results Monday.

On Monday, Roquefort Therapeutics said it made a pretax loss of GBP1.6 million in 2022, widened from GBP917,433 the previous year. It also reported no revenue for last year, down from GBP719 in 2021. The company did not declare a dividend for 2022, unchanged from the prior year.

Current stock price: 6.92 pence, up 1.6% on Wednesday in London

12-month change: down 99%

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.